Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
2.
Nicotine Tob Res ; 2024 May 03.
Article in English | MEDLINE | ID: mdl-38700441
5.
Chest ; 164(6): 1345-1347, 2023 12.
Article in English | MEDLINE | ID: mdl-38070954
7.
Lancet Glob Health ; 11(9): e1338, 2023 09.
Article in English | MEDLINE | ID: mdl-37591578

Subject(s)
Tobacco Control , Humans
13.
Eur Stroke J ; 8(1): 328-333, 2023 03.
Article in English | MEDLINE | ID: mdl-37021190

ABSTRACT

Background: The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk. Methods: This was a post-hoc analysis of the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, which had a 90-day follow-up period. We used multivariable Cox regression and subgroup interaction analysis to determine the effect of smoking on the risk of subsequent ischemic stroke and major hemorrhage, respectively. Results: Data from 4877 participants enrolled in the POINT trial were analyzed. Among these, 1004 were current smokers and 3873 were non-smokers at the time of index event. Smoking was associated with a non-significant trend toward an increased risk of subsequent ischemic stroke during follow up (adjusted HR, 1.31 (95% CI, 0.97-1.78), p = 0.076). The effect of clopidogrel on ischemic stroke did not differ between non-smokers (HR, 0.74 (95% CI, 0.56-0.98), p = 0.03) and smokers (HR, 0.63 (95% CI, 0.37-1.05), p = 0.078), p for interaction = 0.572. Similarly, the effect of clopidogrel on major hemorrhage did not differ between non-smokers (hazard ratio, 1.67 (95% CI, 0.40-7.00), p = 0.481) and smokers (HR, 2.59 (95% CI, 1.08-6.21), p = 0.032), p for interaction = 0.613. Conclusions: In this post-hoc analysis of the POINT trial we found that the effect of clopidogrel on reducing subsequent ischemic stroke as well as risk of major hemorrhage did not depend on smoking status, indicating that smokers benefit to a similar degree from DAPT as non-smokers.


Subject(s)
Ischemic Attack, Transient , Ischemic Stroke , Stroke , Humans , Aspirin/therapeutic use , Clopidogrel/therapeutic use , Hemorrhage/chemically induced , Ischemic Attack, Transient/chemically induced , Ischemic Stroke/epidemiology , Neoplasm Recurrence, Local/chemically induced , Platelet Aggregation Inhibitors/therapeutic use , Smoking/adverse effects , Stroke/chemically induced , Tobacco Smoking
15.
JAMA Netw Open ; 6(2): e2254655, 2023 02 01.
Article in English | MEDLINE | ID: mdl-36745457

ABSTRACT

This cross-sectional study evaluates the association between the 2021 varenicline tartrate recall and prescribing of varenicline and other medications for nicotine dependence in a large US national patient cohort.


Subject(s)
Smoking Cessation , Tobacco Use Disorder , Humans , Varenicline/therapeutic use , Tobacco Use Disorder/drug therapy , Nicotinic Agonists/therapeutic use
17.
Neurocrit Care ; 38(1): 1-6, 2023 02.
Article in English | MEDLINE | ID: mdl-36517662

ABSTRACT

Medicines have been developed and have become globalized at a pace faster than traditional medical education can keep up. Physicians, pharmacists, nurses, and advanced practice providers learn the names and functions of these medications, but not how they are made and how they get to the bedside. The often economically driven intricacies behind these processes have a dramatic effect on patient care and outcomes. A staggering proportion of medications worldwide are reported to be substandard or falsified. This article explores one country's story of how medication gets to the bedside, describes how this process can go wrong, and outlines what providers can do to work toward the goal of equitable access to quality medications for all.


Subject(s)
Counterfeit Drugs , Physicians , Humans , Ecuador , Global Health
18.
Ann Intern Med ; 175(10): 1440-1451, 2022 10.
Article in English | MEDLINE | ID: mdl-36122380

ABSTRACT

DESCRIPTION: In February 2022, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the management of major depressive disorder (MDD). This synopsis summarizes key recommendations. METHODS: Senior leaders within the VA and the DoD assembled a team to update the 2016 CPG for the management of MDD that included clinical stakeholders and conformed to the National Academy of Medicine's tenets for trustworthy CPGs. The guideline panel developed key questions, systematically searched and evaluated the literature, created two 1-page algorithms, and distilled 36 recommendations for care using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Select recommendations that were identified by the authors to represent key changes from the prior CPG are presented in this synopsis. RECOMMENDATIONS: The scope of the CPG is diverse; however, this synopsis focuses on key recommendations that the authors identified as important new evidence and changes to prior recommendations on pharmacologic management, pharmacogenomics, psychotherapy, complementary and alternative therapies, and the use of telemedicine.


Subject(s)
Depressive Disorder, Major , Veterans , Depressive Disorder, Major/therapy , Humans , United States , United States Department of Veterans Affairs
SELECTION OF CITATIONS
SEARCH DETAIL
...